Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).

CONCLUSIONS: FDC improved dyspnoea and lung function compared to aclidinium, formoterol or placebo, and this translated into an increase in the number of responders on combination treatment. Quality of life was better with combination compared to formoterol or placebo. There was no evidence of a difference between FDC and monotherapy or placebo for exacerbations, hospital admissions, mortality, non-fatal SAEs or adverse events. Studies reported a lower risk of moderate exacerbations and adverse events with FDC compared to formoterol; however, larger studies would yield a more precise estimate for these outcomes. PMID: 30536566 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30536566?dopt=Abstract

Source: Cochrane Database of Systematic Reviews - December 11, 2018 Category: General Medicine Authors: Ni H, Moe S, Soe Z, Myint KT, Viswanathan KN Tags: Cochrane Database Syst Rev Source Type: research